Gilead Keeps Focus On HIV, Long-Acting Drugs And Growth Through Oncology

Three Years On, Strategy Under CEO O’Day Is Unchanged

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.